Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
News|Articles|September 29, 2026
Dermatology Times September 2026 Recap
Author(s)Shannon Heaning, Content Associate
Listen
0:00 / 0:00
Key Takeaways
- Guselkumab achieved key phase 4 STAR endpoints in axial PsA, linking clinical improvement to reductions in MRI-detected inflammatory activity.
- Bemotrizinol entry via new US facial sunscreen formulations broadens UV-filter options and signals incremental modernization of domestic photoprotection products.
Dermatology Times is looking back on the top stories in dermatology from the month of September.
Advertisement
From regulatory milestones and late-stage trial results to emerging therapies and expert perspectives, catch up on the dermatology developments that shaped September.
September brought another packed month in dermatology, with new regulatory decisions, pivotal clinical trial readouts, evolving treatment strategies, and conversations with leading experts across medical, surgical, and aesthetic dermatology.
Here’s what you may have missed from Dermatology Times and NPPA Connect this September.
🚨 Clearances, Approvals, Updates, and Recommendations
New approvals, FDA decisions, designations, and pipeline milestones.
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
Guselkumab met the primary and major secondary endpoints in the phase 4 STAR study, demonstrating improvements in axial symptoms and MRI-confirmed inflammation.
Neutrogena Introduces Sunscreens With Bemotrizinol
New facial sunscreen formulations featuring bemotrizinol mark a notable development in US sunscreen innovation and expand the range of available UV filters.
Zasocitinib Earns FDA Priority Review in Plaque Psoriasis
The investigational oral TYK2 inhibitor moved closer to a potential regulatory decision following phase 3 findings in adults with moderate to severe plaque psoriasis.
Dersimelagon Moves Forward Under FDA Priority Review
The investigational oral therapy continues to advance for erythropoietic protoporphyria and X-linked protoporphyria.
🧬 Big Studies and Big Data
The studies, clinical trial results, and emerging science that caught our attention.
ORKA-001 Demonstrates Durable Skin Clearance Through Week 28
New psoriasis findings added to the growing pipeline of therapies designed to deliver deeper and potentially longer-lasting disease control.
Could GLP-1 Therapy Have a Role in Psoriasis?
Emerging research continued to explore the relationship between metabolic health, weight, systemic inflammation, and psoriasis outcomes.
💡 Expert Insights
Clinical perspectives, practical takeaways, and conversations with dermatology leaders.
Everything Clinicians—and Their Patients—Want to Know About the Hair Loss Pipeline
Emerging treatments could reshape conversations around androgenetic alopecia as new mechanisms move through clinical development.
Earlier Biologic Use and Deroofing in Hidradenitis Suppurativa
Alexandra Charrow, MD, discussed earlier intervention, biologic therapy, and procedural approaches to HS during Maui Derm NP+PA Fall 2026.
The Aesthetic Edge: September 2026
September's installment explored products, procedures, and trends shaping conversations in aesthetic dermatology.
✈️ Next Stop: EADV 2026
Dermatology Times is heading to Vienna for the 2026 European Academy of Dermatology and Venereology Congress, where new findings across inflammatory skin disease, psoriasis, atopic dermatitis, lupus, vitiligo, and other areas will take center stage.
Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.
Advertisement
Related to this article
Two new Neutrogena facial sunscreens incorporate bemotrizinol, the first new sunscreen active ingredient added to the US OTC monograph in decades.
From emerging therapies to earlier intervention and psychosocial support, Dermatology Times looks back at key alopecia areata developments in 2026.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Guselkumab met primary and major secondary endpoints in the phase 4 STAR study, improving axial PsA symptoms and MRI-confirmed inflammation.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Alopecia Areata Awareness Month: 2026 in Review
3
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
4
Dermatology Times Spot Test: September 27, 2026
5